07:49 AM EDT, 09/17/2024 (MT Newswires) -- Vigil Neuroscience ( VIGL ) said Tuesday that the US Food and Drug Administration has removed the partial hold on its phase 1 clinical trial of VG-3927, a potential therapy for Alzheimer's disease, based on a complete response it submitted to the agency.

The company said it has started dosing a group of Alzheimer's patients to assess the biomarker response of VG-3927 after a single dose and expects to use this data for the development strategy of subsequent trials.

Vigil said it plans to report the complete phase 1 clinical data in Q1 of 2025.

Shares of the company rose more than 6% in recent premarket activity on Tuesday.

Price: 3.8000, Change: +0.23, Percent Change: +6.44